Table III.

Ultrasound data in each group.

					TU
	PS (n=16)		PL (n=20)		Low-dose (n=20)		High-dose (n=20)
Parameters	6 weeks	18 weeks	6 weeks	18 weeks	6 weeks	18 weeks	6 weeks	18 weeks
IVST	1.47±0.25	1.58±0.24	1.43±0.18	1.58±0.18	1.50±0.39	1.69±0.19	1.51±0.22	1.67±0.20
PWT	1.58±0.27	1.67±0.31	1.60±0.20	1.76±0.28	1.60±0.21	1.77±0.18	1.62±0.21	1.78±0.26
LVEVs	0.12±0.03	0.11±0.04	0.63±0.21	0.67±0.22	0.63±0.20	0.45±0.21	0.61±0.25	0.47±0.18
LVEVd	0.34±0.07	0.36±0.9	0.96±0.20	0.94±0.20	0.93±0.19	0.76±0.23	0.92±0.17	0.79±0.19
LVEF%	88.9±9.7	79.12±8.5	19.3± 3.6a	16.47±4.8a,c	18.21±2.7b	35.25±8.2b,c	18.53±4.0b,c,d	30.89± 7.6c,d

TU, testosterone; PS, pseudosurgery; PL, placebo; IVST, interventricular septal thickness; PWT, posterior wall thickness; LVEF, left ventricular ejection fraction; LVEVs, left ventricular end-systolic volume; LVEVd, left ventricular end-diastolic volume.

^aPL group compared to PS group, P<0.05.

^bTU group compared to PL group, P<0.05.

^cComparison at 6 and 18 weeks within the same group, P<0.05.

^dLow-dose TU group compared to high-dose TU group, P>0.05.